Emerging Risk Profile of Lung Cancer Therapy: Diffuse Alveolar Hemorrhage from Osimertinib.

Case Rep Oncol Med · 2019 · PMC6701301 · PMID 31467750

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Considering more prevalent use of EGFR-TKI, particularly Osimertinib as front-line therapy for NSCLC, it is highly significant to recognize uncommon adverse reactions.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.